TP53 and colorectal carcinoma: As both p53 knockdown and aspartate supplementation reduced the inhibition of cell viability and lessened the decrease in replication fork progression caused by IACS-010759 treatment (Figs. 4F, H and 5I, J), it is likely that p53 affects aspartate levels in CRC cells.